Company launched a unique Toustar pen, along with dedicated ToujeoTM cartridges, addressing the need for a reusable delivery device. Through the Scheme of Arrangement among the Company and Sanofi ...
The table is limited by our hospital pharmacy's formulary; however, our purpose was to update the current literature. The table is intended for use as a guide when medications labeled for ...
Diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant) and inactivated poliovirus vaccine combined Pediarix (GlaxoSmithKline) 24 hr Manufacturer Diphtheria and ...
The 'big three' insulin producers Novo Nordisk, Eli Lilly, and Sanofi are being sued by the ... no more than $30 per vial or $55 for five pen cartridges, adding that compares to around $329 ...
The biosimilars – which will be interchangeable with Sanofi's Lantus (insulin glargine ... vial and no more than $55 for a box of five pen cartridges – which Civica says is "a significant ...
Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era. But even as the billions pile up, Regeneron isn't entirely happy with ...
AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...
© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...
Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. drug ingredients plant tied to its longstanding subsidiary Genzyme.
The Food and Drug Administration has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility in Massachusetts where the company makes ...
Sanofi (SNYNF – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from Bank of America Securities reiterated a Buy rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback